Research advances in major structural proteins of monkeypox virus and its monoclonal antibody
10.3867/j.issn.1000-3002.2025.08441
- VernacularTitle:猴痘病毒主要表面抗原蛋白及其单克隆抗体研究进展
- Author:
Qing ZHANG
1
;
Mengmeng ZHANG
;
Jijun YU
;
Jiannan FENG
;
Yinxiang WEI
;
Jing WANG
Author Information
1. 河南大学抗体药物开发技术国家地方联合工程实验室,河南 开封 475004
- Publication Type:Journal Article
- Keywords:
monkeypox virus;
structural proteins;
mature virion;
extracellular enveloped;
immuno-genicity;
monoclonal antibody;
antibody combination therapy
- From:
Chinese Journal of Pharmacology and Toxicology
2025;39(8):619-630
- CountryChina
- Language:Chinese
-
Abstract:
Monkeypox,caused by the monkeypox virus(MPXV),is a zoonotic infectious disease characterized clinically by fever,rash,and lymphadenopathy.In September 2024,the outbreak of a novel MPXV Clade Ib variant in the Democratic Republic of the Congo was designated by the World Health Organization as a public health emergency of international concern,highlighting deficiencies in current prevention and control systems.Although modified attenuated smallpox vaccines exhibit cross-protective efficacy against MPXV infection,their adverse effects still limit clinical applications.Further-more,the therapeutic efficacy of tecovirimat—the FDA emergency-authorized antiviral drug for Smallpox—is limited.Recent studies have shown that tecovirimat does not significantly improve lesion healing time or reduce overall mortality in patients infected with MPXV CladeⅠ.Monoclonal antibodies,which neutralize viral activity by targeting critical membrane proteins,have emerged as a pivotal strategy to overcome current therapeutic bottlenecks by integrating therapeutic,diagnostic and prophylactic functions.This article reviews the epidemiological and virological characteristics of MPXV,along with functional characteristics of MPXV major membrane proteins,including A29L,A35R,B6R,E8L,M1R and H3L,focusing on the research progress in monoclonal antibodies against these key targets.Their protective effects in vitro/in vivo are explored while such as strategies monoclonal antibody combina-tion therapy are recommended to enhance efficacy and overcome drug resistance.
